These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 25591003)

  • 1. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
    Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
    Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional interplay between MDM2, p63/p73 and mutant p53.
    Stindt MH; Muller PA; Ludwig RL; Kehrloesser S; Dötsch V; Vousden KH
    Oncogene; 2015 Aug; 34(33):4300-10. PubMed ID: 25417702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the K24N mutation on the transactivation domain of p53 and its binding to murine double-minute clone 2.
    Zhan YA; Wu H; Powell AT; Daughdrill GW; Ytreberg FM
    Proteins; 2013 Oct; 81(10):1738-47. PubMed ID: 23609977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of the p53-MDM2 pathway.
    Åberg E; Saccoccia F; Grabherr M; Ore WYJ; Jemth P; Hultqvist G
    BMC Evol Biol; 2017 Aug; 17(1):177. PubMed ID: 28774266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX.
    Levy R; Gregory E; Borcherds W; Daughdrill G
    Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30832340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MDMX acidic domain competes with the p53 transactivation domain for MDM2 N-terminal domain binding.
    Song Q; Liu XQ; Rainey JK
    Biochim Biophys Acta Mol Cell Res; 2022 Oct; 1869(10):119319. PubMed ID: 35780910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding Kinetics of the Intrinsically Disordered p53 Family Transactivation Domains and MDM2.
    Åberg E; Karlsson OA; Andersson E; Jemth P
    J Phys Chem B; 2018 Jul; 122(27):6899-6905. PubMed ID: 29878773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
    Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
    Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the transactivation domains of p53 family members: a computational study.
    Mavinahalli JN; Madhumalar A; Beuerman RW; Lane DP; Verma C
    BMC Genomics; 2010 Feb; 11 Suppl 1(Suppl 1):S5. PubMed ID: 20158876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53 family: at the crossroads in cancer therapy.
    Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
    Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of affinity between p53 transactivation domain and MDM2 across the animal kingdom demonstrates high plasticity of motif-mediated interactions.
    Mihalič F; Åberg E; Farkhondehkish P; Theys N; Andersson E; Jemth P
    Protein Sci; 2023 Jul; 32(7):e4684. PubMed ID: 37211711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways.
    Ha JH; Shin JS; Yoon MK; Lee MS; He F; Bae KH; Yoon HS; Lee CK; Park SG; Muto Y; Chi SW
    J Biol Chem; 2013 Mar; 288(10):7387-98. PubMed ID: 23316052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies raised against Xenopus p53 interact with human p73.
    Le Bras M; Delattre V; Bensaad K; Blandino G; Soussi T
    Oncogene; 2002 Feb; 21(8):1304-8. PubMed ID: 11850851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
    Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
    Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
    Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
    J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 and MDMX can interact differently with ARF and members of the p53 family.
    Wang X; Arooz T; Siu WY; Chiu CH; Lau A; Yamashita K; Poon RY
    FEBS Lett; 2001 Feb; 490(3):202-8. PubMed ID: 11223036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation.
    Burge S; Teufel DP; Townsley FM; Freund SM; Bycroft M; Fersht AR
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3142-7. PubMed ID: 19218448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcellular distribution of p53 and p73 are differentially regulated by MDM2.
    Gu J; Nie L; Kawai H; Yuan ZM
    Cancer Res; 2001 Sep; 61(18):6703-7. PubMed ID: 11559539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the Activity in the p53 Family Depends on the Organization of the Transactivation Domain.
    Krauskopf K; Gebel J; Kazemi S; Tuppi M; Löhr F; Schäfer B; Koch J; Güntert P; Dötsch V; Kehrloesser S
    Structure; 2018 Aug; 26(8):1091-1100.e4. PubMed ID: 30099987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.